Search Results 11-20 of 16553 for ������������KA���:ZA31���24������ ���������������������������������

  1. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...

  2. Mayo Clinic

    Determine the preexisting and therapy-emergent germline and somatic variants associated with an increased risk of clonal and non-clonal cytopenia following CAR- ...

  3. Ketamine Associated ACC GABA and Glutamate Change and Depression Remission - Mayo Clinic

    CYP3A4 inducers carbamazepine and modafinil are prohibited within two weeks prior to administration of study drug and at least 24 hours after last dose of study ...

  4. Uterine fibroids - Doctors and departments - Mayo Clinic

    Learn about these common noncancerous growths and what to do if you have symptoms such as heavy menstrual bleeding.

  5. Holter monitor - Mayo Clinic

    Accessed Jan. 24, 2022. AskMayoExpert. Ambulatory heart rhythm monitoring. Mayo Clinic; 2021. Medical review (expert opinion). Mayo Clinic. Dec. 5, 2018.

  6. Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) - Mayo Clinic

    Study ACT16970 consists of 2 parts (A and B) as follows: Part A is a 24 week, double blind, placebo controlled part, preceded by a screening period of up to ...

  7. CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM - Mayo Clinic

    CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in ...

  8. Publications - Kendall K. Tasche, M.D. - Mayo Clinic

    2025 Jun 1; 46 (5):e198-e201 Epub 2025 Feb 24 ... KA, McGarrah PW, Fuentes Bayne HE, Routman DM ... 2023 Mar-Apr; 44 (2):103806 Epub 2023 Feb 24. View ...

  9. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors - Mayo Clinic

    PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours × 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a ...

  10. A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors - Mayo Clinic

    Sponsor Protocol Number: CGT4859-24-101. About this study. This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what ...